FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894875286> ?p ?o ?g. }

• W2894875286 abstract "Background: Several single chemotherapeutic agents have been evaluated as the second-line treatment of advanced urothelial carcinoma. Despite encouraging efficacy outcomes, toxicity has often led to dose modifications or discontinuation. We aimed to assess the safety of vinflunine in a particular population of advanced transitional cell carcinoma of urothelium (TCCU), that were exposed to the previous toxicity of chemotherapy. Methods: This is an open-label, prospective, single-center pilot study to evaluate the response rate and safety profile of vinflunine in patients with advanced TCCU. It was planned to enroll 25 evaluable patients. Eligible patients are those with progressive disease after first-line platinum-based regimen for advanced or metastatic disease. Results: The study was prematurely closed due to two sudden deaths that were judged by the review board as treatment-related. Only ten patients were evaluated and received at least one cycle of vinflunine. All but one were male and seven underwent radical surgery. Eight had a distant metastasis (mainly lung and/or liver). Disease control rate was 40%, four patients had a partial response with median duration of response of 3.5 months. The median overall survival was 3.2 months (95% CI:1.67- 4.73). There were three serious adverse events namely two sudden deaths and one grade 4 thrombocytopenia. Nine grade 3/4 adverse events occurred. The most common all-grade adverse events were fatigue (50%), constipation (40%) and vomiting (40%). Moreover, grade 3 fatigue occurred in 30% of patients. Only one patient, who achieved PR for 5 months, was fit to receive further cytotoxic chemotherapy. Conclusion: The activity of vinflunine in advanced urothelial carcinoma came at the expense of its safety. The use of vinflunine has to be limited to the selected group of patients. However, this is a single institute experience in a limited number of patients." @default.
• W2894875286 created "2018-10-12" @default.
• W2894875286 creator A5011483509 @default.
• W2894875286 creator A5021120494 @default.
• W2894875286 creator A5021361330 @default.
• W2894875286 creator A5058185123 @default.
• W2894875286 creator A5075646729 @default.
• W2894875286 creator A5079586786 @default.
• W2894875286 date "2019-01-17" @default.
• W2894875286 modified "2023-10-14" @default.
• W2894875286 title "Safety of Vinflunine in Patients with Advanced Urothelial Carcinoma Refractory to Platinum-based Chemotherapy: A Prospective Pilot Study" @default.
• W2894875286 cites W1480673074 @default.
• W2894875286 cites W177596921 @default.
• W2894875286 cites W1858135205 @default.
• W2894875286 cites W1998119353 @default.
• W2894875286 cites W2037596540 @default.
• W2894875286 cites W2040377946 @default.
• W2894875286 cites W2053169311 @default.
• W2894875286 cites W2066984265 @default.
• W2894875286 cites W2102116016 @default.
• W2894875286 cites W2103201965 @default.
• W2894875286 cites W2105228765 @default.
• W2894875286 cites W2154029052 @default.
• W2894875286 cites W2259411705 @default.
• W2894875286 cites W2312726115 @default.
• W2894875286 cites W2313972367 @default.
• W2894875286 cites W2318108446 @default.
• W2894875286 cites W2334797339 @default.
• W2894875286 cites W2533194337 @default.
• W2894875286 cites W2552075586 @default.
• W2894875286 cites W2588916311 @default.
• W2894875286 cites W2604409043 @default.
• W2894875286 cites W2766396505 @default.
• W2894875286 cites W2782994772 @default.
• W2894875286 cites W2784433559 @default.
• W2894875286 cites W2790214444 @default.
• W2894875286 cites W2792717752 @default.
• W2894875286 cites W4246715702 @default.
• W2894875286 doi "https://doi.org/10.2174/1574886313666181001120752" @default.
• W2894875286 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30277164" @default.
• W2894875286 hasPublicationYear "2019" @default.
• W2894875286 type Work @default.
• W2894875286 sameAs 2894875286 @default.
• W2894875286 citedByCount "0" @default.
• W2894875286 crossrefType "journal-article" @default.
• W2894875286 hasAuthorship W2894875286A5011483509 @default.
• W2894875286 hasAuthorship W2894875286A5021120494 @default.
• W2894875286 hasAuthorship W2894875286A5021361330 @default.
• W2894875286 hasAuthorship W2894875286A5058185123 @default.
• W2894875286 hasAuthorship W2894875286A5075646729 @default.
• W2894875286 hasAuthorship W2894875286A5079586786 @default.
• W2894875286 hasConcept C121608353 @default.
• W2894875286 hasConcept C126322002 @default.
• W2894875286 hasConcept C141071460 @default.
• W2894875286 hasConcept C143998085 @default.
• W2894875286 hasConcept C197934379 @default.
• W2894875286 hasConcept C2776694085 @default.
• W2894875286 hasConcept C2778375690 @default.
• W2894875286 hasConcept C2778715236 @default.
• W2894875286 hasConcept C2778822529 @default.
• W2894875286 hasConcept C2780352672 @default.
• W2894875286 hasConcept C2780580376 @default.
• W2894875286 hasConcept C2781413609 @default.
• W2894875286 hasConcept C2908647359 @default.
• W2894875286 hasConcept C2911057145 @default.
• W2894875286 hasConcept C3019882237 @default.
• W2894875286 hasConcept C71924100 @default.
• W2894875286 hasConcept C99454951 @default.
• W2894875286 hasConceptScore W2894875286C121608353 @default.
• W2894875286 hasConceptScore W2894875286C126322002 @default.
• W2894875286 hasConceptScore W2894875286C141071460 @default.
• W2894875286 hasConceptScore W2894875286C143998085 @default.
• W2894875286 hasConceptScore W2894875286C197934379 @default.
• W2894875286 hasConceptScore W2894875286C2776694085 @default.
• W2894875286 hasConceptScore W2894875286C2778375690 @default.
• W2894875286 hasConceptScore W2894875286C2778715236 @default.
• W2894875286 hasConceptScore W2894875286C2778822529 @default.
• W2894875286 hasConceptScore W2894875286C2780352672 @default.
• W2894875286 hasConceptScore W2894875286C2780580376 @default.
• W2894875286 hasConceptScore W2894875286C2781413609 @default.
• W2894875286 hasConceptScore W2894875286C2908647359 @default.
• W2894875286 hasConceptScore W2894875286C2911057145 @default.
• W2894875286 hasConceptScore W2894875286C3019882237 @default.
• W2894875286 hasConceptScore W2894875286C71924100 @default.
• W2894875286 hasConceptScore W2894875286C99454951 @default.
• W2894875286 hasLocation W28948752861 @default.
• W2894875286 hasLocation W28948752862 @default.
• W2894875286 hasOpenAccess W2894875286 @default.
• W2894875286 hasPrimaryLocation W28948752861 @default.
• W2894875286 hasRelatedWork W1492384425 @default.
• W2894875286 hasRelatedWork W1972179746 @default.
• W2894875286 hasRelatedWork W1973342136 @default.
• W2894875286 hasRelatedWork W2007986200 @default.
• W2894875286 hasRelatedWork W2104761597 @default.
• W2894875286 hasRelatedWork W2372442000 @default.
• W2894875286 hasRelatedWork W2384102814 @default.
• W2894875286 hasRelatedWork W2394317912 @default.
• W2894875286 hasRelatedWork W2528959283 @default.
• W2894875286 hasRelatedWork W2183331092 @default.
• W2894875286 isParatext "false" @default.

• next